Stem cell study for COVID lung failure pulled before it began
Disease control
Terminated
This study planned to test a new stem cell product (BX-U001) in people with severe COVID-19 pneumonia and moderate to severe lung failure (ARDS). The goal was to check safety and find the best dose. However, the study was withdrawn before enrolling any participants, so no results…
Phase: PHASE1, PHASE2 • Sponsor: Baylx Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC